Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Aiach

Showing results (51-60 of 236) with videos related to

Pageof 24
Sort By:
FEBS Letters|August 26, 1998
A monoclonal antibody recognizing the activation domain of protein C in its calcium-free conformationA Vincenot, J L Pittet, M Aiach, et al.
Nephron|January 1, 1995
Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndromeM Alhenc-Gelas, J Rossert, C Jacquot, et al.
La Nouvelle Presse Medicale|January 14, 1978
[Changes in antithrombin III during treatment with heparin]M Aiach, J Beuvin, A Michaud, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1982
Determination of factor X and heparin with chromogenic substrateM Aiach, A Michaud, L Capron, et al.
The Journal of Biological Chemistry|February 4, 1994
Activation-induced exposure of the thrombin anion-binding exosite. Interactions of recombinant mutant prothrombins with thrombomodulin and a thrombin exosite-specific antibodyQ Wu, V Picard, M Aiach, et al.
Thrombosis and Haemostasis|May 1, 1996
Absence of length polymorphism within the 31 tandem repeats of the B domain of factor VM Escoffre-Barbe, M Alhenc-Gelas, M Aiach, et al.
Annales De Medecine Interne|January 1, 1986
[Low-molecular weight heparins. Prospects in 1985]M Aiach, J N Fiessinger, J F Vitoux, et al.
Thrombosis and Haemostasis|February 3, 1992
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosisJ M Costa, J N Fiessinger, L Capron, et al.
Thrombosis and Haemostasis|February 11, 2000
Thirty-three novel mutations in the protein C gene. French INSERM network on molecular abnormalities responsible for protein C and protein SM Alhenc-Gelas, S Gandrille, M L Aubry, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Resistance to activated protein C: role in venous and arterial thrombosisJ Emmerich, M Alhenc-Gelas, M Aiach, et al.
Pageof 24

Showing results (51-60 of 236) with videos related to

Sort By:
Pageof 24
FEBS Letters|August 26, 1998
A monoclonal antibody recognizing the activation domain of protein C in its calcium-free conformationA Vincenot, J L Pittet, M Aiach, et al.
Nephron|January 1, 1995
Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndromeM Alhenc-Gelas, J Rossert, C Jacquot, et al.
La Nouvelle Presse Medicale|January 14, 1978
[Changes in antithrombin III during treatment with heparin]M Aiach, J Beuvin, A Michaud, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1982
Determination of factor X and heparin with chromogenic substrateM Aiach, A Michaud, L Capron, et al.
The Journal of Biological Chemistry|February 4, 1994
Activation-induced exposure of the thrombin anion-binding exosite. Interactions of recombinant mutant prothrombins with thrombomodulin and a thrombin exosite-specific antibodyQ Wu, V Picard, M Aiach, et al.
Thrombosis and Haemostasis|May 1, 1996
Absence of length polymorphism within the 31 tandem repeats of the B domain of factor VM Escoffre-Barbe, M Alhenc-Gelas, M Aiach, et al.
Annales De Medecine Interne|January 1, 1986
[Low-molecular weight heparins. Prospects in 1985]M Aiach, J N Fiessinger, J F Vitoux, et al.
Thrombosis and Haemostasis|February 3, 1992
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosisJ M Costa, J N Fiessinger, L Capron, et al.
Thrombosis and Haemostasis|February 11, 2000
Thirty-three novel mutations in the protein C gene. French INSERM network on molecular abnormalities responsible for protein C and protein SM Alhenc-Gelas, S Gandrille, M L Aubry, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Resistance to activated protein C: role in venous and arterial thrombosisJ Emmerich, M Alhenc-Gelas, M Aiach, et al.
Pageof 24